Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome

Next Previous
Trial Profile

Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam in Children and Adolescents With Tourette's Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ecopipam (Primary)
  • Indications Gilles de la Tourette's syndrome
  • Focus Therapeutic Use
  • Acronyms D1AMOND
  • Sponsors Emalex Biosciences

Most Recent Events

  • 18 Apr 2024 Results evaluating the effect of ecopipam on measures of attention-deficit hyperactivity disorder (ADHD), anxiety disorders (ANX), obsessive-compulsive disorder (OCD) and depression, presented at the 76th Annual Meeting of the American Academy of Neurology 2024
  • 01 Apr 2024 According to a Paragon Biosciences media release, the data from this trial will be presented at the at the AAN Annual Meeting, 2024.
  • 27 Apr 2023 Results of a PopPK model analysis using data from this trial presented at the 75th Annual Meeting of the American Academy of Neurology 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top